Muhammad Burhan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Muhammad Burhan has a total of 134 co-authors. Here are the top co-authors by number of shared publications:
- Taha Ibrahim
Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan
8 shared publications - Saad Ashraf
Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan
6 shared publications - Ahila Ali
Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan
5 shared publications - Ibrahim Nagmeldin Hassan
University of Khartoum Faculty of Medicine Khartoum Sudan
5 shared publications - Ayan Khalid
Department of Medicine Dow University of Health Sciences Karachi Pakistan
4 shared publications - Hafiza Tooba Siddiqui
Jinnah Sindh Medical University, Karachi, Pakistan
4 shared publications
Latest Publications
- Open Access
- 19 October 2026
- Published by Springer Nature in BMC Neurology
Safety and efficacy of evobrutinib in relapsing multiple sclerosis: a GRADE-assessed systematic review and meta-analysis
- 19 October 2026
- Published by Springer Nature in BMC Neurology
Open AccessSafety and efficacy of evobrutinib in relapsing multiple sclerosis: a GRADE-assessed systematic review and meta-analysis
- 15 October 2026
- Published by SAGE Publications in Annals of Pharmacotherapy
Efficacy and Safety of Tradipitant for Motion Sickness—A GRADE Assessed Systematic Review and Meta-Analysis
Objective: To evaluate the efficacy and safety of tradipitant, a neurokinin-1 (NK1) receptor antagonist, for preventing motion sickness–induced vomiting. Data Sources: PubMed/MEDLINE, Embase, Scopus, and ClinicalTrials.gov were searched from inception through February 2026 without language or date resrictions. Study Selection and Data Extraction: Randomized controlled trials comparing tradipitant (85 or 170 mg) with placebo in adults with motion sickness were included. Two reviewers independently screened studies, extracted data, assessed risk of bias using Cochrane Risk of Bias 2, and evaluated certainty of evidence using Grading of Recommendations Assessment, Development, and Evaluation. Data Synthesis: Three randomized controlled trials (N = 808) were included. Tradipitant significantly reduced overall vomiting vs placebo (risk ratio [RR], 0.38; 95% confidence interval [CI], 0.30-0.48; I 2 = 0%) and improved the composite nausea/vomiting outcome (RR, 0.48; 95% CI, 0.35-0.65). Serious adverse events and somnolence were comparable between groups, although fatigue was more frequent with tradipitant (RR, 2.66; 95% CI, 1.02-6.93). Relevance to Patient Care and Clinical Practice in Comparison to Existing Drugs: Unlike antihistamines and anticholinergics, which are frequently limited by sedation and anticholinergic adverse effects, tradipitant significantly reduces motion-induced vomiting with minimal sedation and may benefit patients who do not respond to or cannot tolerate conventional therapies. Conclusions: Tradipitant significantly reduces motion sickness–induced vomiting while maintaining a favorable safety profile, supporting its role as an effective treatment option pending further comparative studies.
- 15 October 2026
- Published by SAGE Publications in Annals of Pharmacotherapy
Efficacy and Safety of Tradipitant for Motion Sickness—A GRADE Assessed Systematic Review and Meta-Analysis
Objective: To evaluate the efficacy and safety of tradipitant, a neurokinin-1 (NK1) receptor antagonist, for preventing motion sickness–induced vomiting. Data Sources: PubMed/MEDLINE, Embase, Scopus, and ClinicalTrials.gov were searched from inception through February 2026 without language or date resrictions. Study Selection and Data Extraction: Randomized controlled trials comparing tradipitant (85 or 170 mg) with placebo in adults with motion sickness were included. Two reviewers independently screened studies, extracted data, assessed risk of bias using Cochrane Risk of Bias 2, and evaluated certainty of evidence using Grading of Recommendations Assessment, Development, and Evaluation. Data Synthesis: Three randomized controlled trials (N = 808) were included. Tradipitant significantly reduced overall vomiting vs placebo (risk ratio [RR], 0.38; 95% confidence interval [CI], 0.30-0.48; I 2 = 0%) and improved the composite nausea/vomiting outcome (RR, 0.48; 95% CI, 0.35-0.65). Serious adverse events and somnolence were comparable between groups, although fatigue was more frequent with tradipitant (RR, 2.66; 95% CI, 1.02-6.93). Relevance to Patient Care and Clinical Practice in Comparison to Existing Drugs: Unlike antihistamines and anticholinergics, which are frequently limited by sedation and anticholinergic adverse effects, tradipitant significantly reduces motion-induced vomiting with minimal sedation and may benefit patients who do not respond to or cannot tolerate conventional therapies. Conclusions: Tradipitant significantly reduces motion sickness–induced vomiting while maintaining a favorable safety profile, supporting its role as an effective treatment option pending further comparative studies.
- 9 September 2026
- Published by SAGE Publications in Annals of Pharmacotherapy
Efficacy and Safety of Fremanezumab in Episodic Migraine: A Systematic Review and Meta-analysis
Background: Fremanezumab, a calcitonin gene-related peptide monoclonal antibody, is approved for migraine prevention, yet evidence specific to episodic migraine remains limited. We synthesized randomized evidence on its efficacy and safety. Methods: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PROSPERO CRD420261385104), we systematically searched PubMed, Embase, and Scopus from inception to June 5, 2026, for placebo-controlled randomized controlled trials (RCTs) evaluating fremanezumab for episodic migraine prevention. Primary outcomes were the ≥50% responder rate and change in monthly migraine days. Random-effects meta-analyses were performed, and risk of bias was assessed using the Cochrane RoB 2 tool. Results: Four RCTs including 1764 participants were included. Fremanezumab significantly increased the ≥50% responder rate (risk ratio: 1.81, 95% CI: 1.53-2.15) and reduced monthly migraine days (mean difference: −1.98, 95% CI: −2.93 to −1.03), headache days, acute medication-use days, and migraine-related disability. Overall safety was comparable to placebo, with no significant differences in treatment-emergent adverse events, serious adverse events, or treatment discontinuations; injection-site induration occurred more frequently with fremanezumab. Relevance to Patient Care and Clinical Practice: This meta-analysis strengthens the evidence supporting fremanezumab as an effective and generally well-tolerated preventive therapy for episodic migraine. The demonstrated reductions in migraine frequency, disability, and acute medication use, together with flexible monthly and quarterly dosing, support its use in appropriately selected patients and may facilitate individualized treatment decisions by clinicians and pharmacists. Although the inclusion of pediatric data expands the current evidence base, these findings should be interpreted cautiously because they are derived from a single randomized trial. Conclusion: Fremanezumab is an effective and generally well-tolerated preventive treatment for episodic migraine. Evidence is robust in adults, whereas pediatric findings remain preliminary and warrant confirmation in future randomized trials.
- 9 September 2026
- Published by SAGE Publications in Annals of Pharmacotherapy
Efficacy and Safety of Fremanezumab in Episodic Migraine: A Systematic Review and Meta-analysis
Background: Fremanezumab, a calcitonin gene-related peptide monoclonal antibody, is approved for migraine prevention, yet evidence specific to episodic migraine remains limited. We synthesized randomized evidence on its efficacy and safety. Methods: Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PROSPERO CRD420261385104), we systematically searched PubMed, Embase, and Scopus from inception to June 5, 2026, for placebo-controlled randomized controlled trials (RCTs) evaluating fremanezumab for episodic migraine prevention. Primary outcomes were the ≥50% responder rate and change in monthly migraine days. Random-effects meta-analyses were performed, and risk of bias was assessed using the Cochrane RoB 2 tool. Results: Four RCTs including 1764 participants were included. Fremanezumab significantly increased the ≥50% responder rate (risk ratio: 1.81, 95% CI: 1.53-2.15) and reduced monthly migraine days (mean difference: −1.98, 95% CI: −2.93 to −1.03), headache days, acute medication-use days, and migraine-related disability. Overall safety was comparable to placebo, with no significant differences in treatment-emergent adverse events, serious adverse events, or treatment discontinuations; injection-site induration occurred more frequently with fremanezumab. Relevance to Patient Care and Clinical Practice: This meta-analysis strengthens the evidence supporting fremanezumab as an effective and generally well-tolerated preventive therapy for episodic migraine. The demonstrated reductions in migraine frequency, disability, and acute medication use, together with flexible monthly and quarterly dosing, support its use in appropriately selected patients and may facilitate individualized treatment decisions by clinicians and pharmacists. Although the inclusion of pediatric data expands the current evidence base, these findings should be interpreted cautiously because they are derived from a single randomized trial. Conclusion: Fremanezumab is an effective and generally well-tolerated preventive treatment for episodic migraine. Evidence is robust in adults, whereas pediatric findings remain preliminary and warrant confirmation in future randomized trials.
- 7 September 2026
- Published by SAGE Publications in Annals of Pharmacotherapy
Efficacy and Safety of Baxdrostat in Hypertension: A GRADE-Assessed Systematic Review and Meta-Analysis of Randomized Controlled Trials
Background: Baxdrostat, a selective aldosterone synthase inhibitor, has emerged as a novel therapy for uncontrolled or resistant hypertension; however, randomized controlled trials (RCTs) have shown variable results. Objective: To evaluate the efficacy and safety of baxdrostat compared with placebo or standard care in patients with uncontrolled or resistant hypertension. Methods: We conducted a Preferred Reporting Items for Systematic Reviews and Meta-analyses–compliant systematic review and meta-analysis of RCTs. PubMed, Embase, Scopus, Cochrane Library, and ClinicalTrials.gov were searched from inception to March 2026. Random-effects models were used to pool standardized mean differences (SMDs) and risk ratios (RRs). Certainty of evidence was assessed using Grading of Recommendations Assessment, Development, and Evaluation (GRADE). Results: Five RCTs (n = 1724) were included. Baxdrostat significantly reduced systolic blood pressure (SMD = −0.40; 95% CI = −0.59 to −0.22; P < .001) and diastolic blood pressure (SMD = −0.29; 95% CI = −0.47 to −0.11; P = .001), and increased achievement of blood pressure control P < .001). It reduced serum sodium (SMD = −0.63; 95% CI = −0.80 to −0.47) but increased serum potassium (SMD = 0.91; 95% CI = 0.77-1.05), hyperkalemia (RR = 10.22; 95% CI = 4.22-24.73), and hyponatremia (RR = 2.90; 95% CI = 1.82-4.61). A modest decline in eGFR was observed (SMD = −0.49; 95% CI = −0.65 to −0.34). Serious adverse events and mortality were not significantly different. Evidence certainty was moderate to high. Conclusion and Relevance: Baxdrostat significantly improves blood pressure control in patients with uncontrolled or resistant hypertension but increases the risk of hyperkalemia and other electrolyte disturbances. These findings strengthen the evidence for selective aldosterone synthase inhibition as a therapeutic approach for aldosterone-mediated hypertension and suggest that baxdrostat may provide an additional treatment option, particularly for patients who remain uncontrolled or cannot tolerate mineralocorticoid receptor antagonists. However, the increased risk of hyperkalemia and the limited duration of available trials highlight the need for careful electrolyte and renal monitoring and further studies evaluating long-term cardiovascular outcomes and comparisons with established therapies.
- 7 September 2026
- Published by SAGE Publications in Annals of Pharmacotherapy
Efficacy and Safety of Baxdrostat in Hypertension: A GRADE-Assessed Systematic Review and Meta-Analysis of Randomized Controlled Trials
Background: Baxdrostat, a selective aldosterone synthase inhibitor, has emerged as a novel therapy for uncontrolled or resistant hypertension; however, randomized controlled trials (RCTs) have shown variable results. Objective: To evaluate the efficacy and safety of baxdrostat compared with placebo or standard care in patients with uncontrolled or resistant hypertension. Methods: We conducted a Preferred Reporting Items for Systematic Reviews and Meta-analyses–compliant systematic review and meta-analysis of RCTs. PubMed, Embase, Scopus, Cochrane Library, and ClinicalTrials.gov were searched from inception to March 2026. Random-effects models were used to pool standardized mean differences (SMDs) and risk ratios (RRs). Certainty of evidence was assessed using Grading of Recommendations Assessment, Development, and Evaluation (GRADE). Results: Five RCTs (n = 1724) were included. Baxdrostat significantly reduced systolic blood pressure (SMD = −0.40; 95% CI = −0.59 to −0.22; P < .001) and diastolic blood pressure (SMD = −0.29; 95% CI = −0.47 to −0.11; P = .001), and increased achievement of blood pressure control P < .001). It reduced serum sodium (SMD = −0.63; 95% CI = −0.80 to −0.47) but increased serum potassium (SMD = 0.91; 95% CI = 0.77-1.05), hyperkalemia (RR = 10.22; 95% CI = 4.22-24.73), and hyponatremia (RR = 2.90; 95% CI = 1.82-4.61). A modest decline in eGFR was observed (SMD = −0.49; 95% CI = −0.65 to −0.34). Serious adverse events and mortality were not significantly different. Evidence certainty was moderate to high. Conclusion and Relevance: Baxdrostat significantly improves blood pressure control in patients with uncontrolled or resistant hypertension but increases the risk of hyperkalemia and other electrolyte disturbances. These findings strengthen the evidence for selective aldosterone synthase inhibition as a therapeutic approach for aldosterone-mediated hypertension and suggest that baxdrostat may provide an additional treatment option, particularly for patients who remain uncontrolled or cannot tolerate mineralocorticoid receptor antagonists. However, the increased risk of hyperkalemia and the limited duration of available trials highlight the need for careful electrolyte and renal monitoring and further studies evaluating long-term cardiovascular outcomes and comparisons with established therapies.
- 10 August 2026
- Published by Taylor & Francis in Seminars in Ophthalmology
- p. 1-11
Efficacy and Safety of Aceclidine in Presbyopia, a Systematic Review and Meta -Analysis
Presbyopia, an age-related oculopathy in which a decline in accommodation capabilities results in difficulties in near vision tasks and hence compromises the performance of essential activities of ...
- 10 August 2026
- Published by Taylor & Francis in Seminars in Ophthalmology
- p. 1-11
Efficacy and Safety of Aceclidine in Presbyopia, a Systematic Review and Meta -Analysis
Presbyopia, an age-related oculopathy in which a decline in accommodation capabilities results in difficulties in near vision tasks and hence compromises the performance of essential activities of ...
- 6 July 2026
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 88 (5) , 355-363
Safety and Efficacy of Lorundrostat in Uncontrolled Hypertension: A Systematic Review and Meta-analysis
Uncontrolled hypertension remains a major global health concern and a leading cause of cardiovascular morbidity and mortality. Aldosterone dysregulation plays a critical role in resistant hypertension, and lorundrostat, a novel aldosterone synthase inhibitor, offers a promising therapeutic approach by directly inhibiting aldosterone production. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of lorundrostat in adults with uncontrolled hypertension. Comprehensive searches of MEDLINE (PubMed), ScienceDirect, Google Scholar, and Cochrane databases were conducted up to July 2025 following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, with the protocol registered on PROSPERO (CRD420251091117). Three randomized controlled trials involving 1568 participants (1165 lorundrostat and 403 placebo) were included, all demonstrating low risk of bias. Pooled analysis revealed that lorundrostat significantly reduced systolic blood pressure (BP) (−8.50 mm Hg, 95% confidence interval: –11.63 to −5.36, P < 0.00001) and diastolic BP (−3.53 mm Hg, 95% confidence interval: –5.61 to −1.45, P = 0.0009) compared with placebo, with no heterogeneity observed. However, lorundrostat was associated with higher risks of hyperkalemia (RR = 5.84, P = 0.01), symptomatic hypotension (RR = 2.98, P = 0.03), serious adverse events (RR = 3.31, P = 0.03), and hyponatremia (RR = 2.03, P = 0.01), although there were no significant differences in moderate or severe adverse events or reduction in kidney function. Publication bias was noted for diastolic BP and selected safety outcomes. In conclusion, lorundrostat demonstrates clinically meaningful BP reduction in uncontrolled hypertension compared with placebo, but with an increased risk of electrolyte disturbances and hypotension. Cautious use and close monitoring are warranted, and larger, long-term trials are needed to further define its safety and therapeutic role.
- 6 July 2026
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 88 (5) , 355-363
Safety and Efficacy of Lorundrostat in Uncontrolled Hypertension: A Systematic Review and Meta-analysis
Uncontrolled hypertension remains a major global health concern and a leading cause of cardiovascular morbidity and mortality. Aldosterone dysregulation plays a critical role in resistant hypertension, and lorundrostat, a novel aldosterone synthase inhibitor, offers a promising therapeutic approach by directly inhibiting aldosterone production. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of lorundrostat in adults with uncontrolled hypertension. Comprehensive searches of MEDLINE (PubMed), ScienceDirect, Google Scholar, and Cochrane databases were conducted up to July 2025 following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, with the protocol registered on PROSPERO (CRD420251091117). Three randomized controlled trials involving 1568 participants (1165 lorundrostat and 403 placebo) were included, all demonstrating low risk of bias. Pooled analysis revealed that lorundrostat significantly reduced systolic blood pressure (BP) (−8.50 mm Hg, 95% confidence interval: –11.63 to −5.36, P < 0.00001) and diastolic BP (−3.53 mm Hg, 95% confidence interval: –5.61 to −1.45, P = 0.0009) compared with placebo, with no heterogeneity observed. However, lorundrostat was associated with higher risks of hyperkalemia (RR = 5.84, P = 0.01), symptomatic hypotension (RR = 2.98, P = 0.03), serious adverse events (RR = 3.31, P = 0.03), and hyponatremia (RR = 2.03, P = 0.01), although there were no significant differences in moderate or severe adverse events or reduction in kidney function. Publication bias was noted for diastolic BP and selected safety outcomes. In conclusion, lorundrostat demonstrates clinically meaningful BP reduction in uncontrolled hypertension compared with placebo, but with an increased risk of electrolyte disturbances and hypotension. Cautious use and close monitoring are warranted, and larger, long-term trials are needed to further define its safety and therapeutic role.
- Open Access
- 13 May 2026
- Published by Wiley in Clinical Cardiology
- Vol. 49 (5) , e70346
Comment on “Updated Meta‐Analysis of Left Bundle Branch Area Pacing Versus Right Ventricular Pacing in Conduction System Disorders: Insights From New Evidence”
- 13 May 2026
- Published by Wiley in Clinical Cardiology
- Vol. 49 (5) , e70346
Open AccessComment on “Updated Meta‐Analysis of Left Bundle Branch Area Pacing Versus Right Ventricular Pacing in Conduction System Disorders: Insights From New Evidence”
- Open Access
- 12 May 2026
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 9 (3) , e70238
Glycaemic and Cardiometabolic Outcomes of Empagliflozin Versus Sitagliptin Added to Metformin in T 2 DM : Insights From a Systematic Review and Meta‐Analysis
Background: Type 2 diabetes mellitus (T2DM) often requires combination therapy when metformin alone becomes insufficient. Empagliflozin (SGLT2 inhibitor) and sitagliptin (DPP‐4 inhibitor) are commonly used add‐on agents with differing metabolic profiles. This systematic review and meta‐analysis compared their glycaemic, cardiometabolic and safety outcomes when added to metformin. Methods: Following PRISMA guidelines, PubMed, Embase, Cochrane, Scopus and ClinicalTrials.gov were searched from inception to September 2025. Randomized trials and observational studies comparing empagliflozin + metformin versus sitagliptin + metformin in adults with T2DM were included. Primary outcomes were changes in HbA1c, body weight, fasting glucose, lipid profile and blood pressure. Safety outcomes included urinary tract infections, genital infections, gastrointestinal disturbances and rash. Risk of bias was assessed using RoB 2.0 and the Newcastle–Ottawa Scale. Random‐effects models were used for meta‐analyses, and meta‐regression explored the impact of empagliflozin dose. Results: Eleven studies met eligibility criteria. Empagliflozin produced greater reductions in HbA1c, body weight, fasting glucose and systolic blood pressure compared with sitagliptin. Lipid changes were modest and inconsistent. Rates of urinary infections, gastrointestinal symptoms and rash were comparable between groups, whereas genital infections were significantly higher with empagliflozin. Rare but serious adverse events associated with SGLT2 inhibitors, including Fournier's gangrene and lower limb amputations, were not reported in the included trials. Meta‐regression showed no meaningful dose–response relationship for glycaemic or weight outcomes. Conclusions: In patients with T2DM on metformin, empagliflozin offers superior glycaemic and cardiometabolic benefits compared with sitagliptin, with an increase in genital infections. Both therapies are well tolerated, supporting empagliflozin as an effective metabolic add‐on option. Trial Registration: PROSPERO ID: CRD420251152360
- 12 May 2026
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 9 (3) , e70238
Open AccessGlycaemic and Cardiometabolic Outcomes of Empagliflozin Versus Sitagliptin Added to Metformin in T 2 DM : Insights From a Systematic Review and Meta‐Analysis
Background: Type 2 diabetes mellitus (T2DM) often requires combination therapy when metformin alone becomes insufficient. Empagliflozin (SGLT2 inhibitor) and sitagliptin (DPP‐4 inhibitor) are commonly used add‐on agents with differing metabolic profiles. This systematic review and meta‐analysis compared their glycaemic, cardiometabolic and safety outcomes when added to metformin. Methods: Following PRISMA guidelines, PubMed, Embase, Cochrane, Scopus and ClinicalTrials.gov were searched from inception to September 2025. Randomized trials and observational studies comparing empagliflozin + metformin versus sitagliptin + metformin in adults with T2DM were included. Primary outcomes were changes in HbA1c, body weight, fasting glucose, lipid profile and blood pressure. Safety outcomes included urinary tract infections, genital infections, gastrointestinal disturbances and rash. Risk of bias was assessed using RoB 2.0 and the Newcastle–Ottawa Scale. Random‐effects models were used for meta‐analyses, and meta‐regression explored the impact of empagliflozin dose. Results: Eleven studies met eligibility criteria. Empagliflozin produced greater reductions in HbA1c, body weight, fasting glucose and systolic blood pressure compared with sitagliptin. Lipid changes were modest and inconsistent. Rates of urinary infections, gastrointestinal symptoms and rash were comparable between groups, whereas genital infections were significantly higher with empagliflozin. Rare but serious adverse events associated with SGLT2 inhibitors, including Fournier's gangrene and lower limb amputations, were not reported in the included trials. Meta‐regression showed no meaningful dose–response relationship for glycaemic or weight outcomes. Conclusions: In patients with T2DM on metformin, empagliflozin offers superior glycaemic and cardiometabolic benefits compared with sitagliptin, with an increase in genital infections. Both therapies are well tolerated, supporting empagliflozin as an effective metabolic add‐on option. Trial Registration: PROSPERO ID: CRD420251152360